Literature DB >> 28926401

The missing 27.

Adam Akullian1, Anna Bershteyn, Britta Jewell, Carol S Camlin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28926401      PMCID: PMC5673304          DOI: 10.1097/QAD.0000000000001638

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
Though a wide body of observational and model-based evidence underscores the promise of Universal Test and Treat (UTT) to reduce population-level HIV incidence in high-burden areas of Sub-Saharan Africa (SSA) [1,2], the only cluster-randomized trial of UTT completed to date, ANRS 12249, did not show a significant reduction in incidence [3]. More UTT trials are currently underway, and some have already exceeded the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90–90–90 targets [4,5]. Still, even with high test and treat coverage, it is unknown whether ongoing trials will engage populations with the greatest potential for onward transmission to achieve the ambitious goal of reducing new HIV infections by 90% between 2010 and 2013 [6]. Ultimately, even strategies that successfully meet or exceed the 90–90–90 targets will leave up to 27% of people living with HIV/AIDS virally nonsuppressed. The epidemiological profile of the ‘missing 27%’ – including their risk behavior, mobility, and network connectedness – is not well understood and must be better characterized to fully evaluate the effectiveness of UTT. Part of the uncertainty in UTT's effectiveness rests in the risk profile of people living with HIV/AIDS (PLWHA) who fail to achieve viral suppression. Mathematical modeling has provided optimistic projections for the population-level effect of UTT on the course of the HIV epidemic [7], with the size of the effect depending on epidemiologic context [8]. These models, however, are subject to varying degrees of parametric uncertainty and often rely on simplistic assumptions about transmission heterogeneity across the HIV cascade of care [7,9-11]. In contrast to common model-based assumptions, engagement in the cascade of care is not independent of transmission potential [12,13]. In the cluster-randomized ANRS 12249 and HIV Prevention Trials Network (HVTN) 071 Population Effects of Antiretroviral Therapy to reduce HIV Transmission (PopART) trials, for example, those unlinked to care tended to be younger [14-16] and in less-stable relationships [14,15]. In the Sustainable East Africa Research in Community Health (SEARCH) cluster-randomized test and treat study, viral suppression at 2-years post intervention was two-fold lower among 15–24-year-old HIV-positive individuals compared with those over 44 years [5]. Age disparities in viral suppression within UTT is concerning given that younger populations may play a larger role in transmission than previously thought [17]. Model-based estimates of UTT effectiveness have also yet to consider the effect of mobile populations – who are at high risk of HIV acquisition and transmission [18], and are among the most difficult to engage in the cascade of care [19] – on UTT. Mobile populations tend to be younger, more likely to be living with HIV, and more likely to engage in higher-risk sexual behavior [20-22]. Given the unique risk profile and lower propensity to engage in the cascade of care among mobile populations, there is a need to incorporate more complex dimensions of population mobility into existing models of population-level UTT effectiveness. Novel approaches that adapt prevention strategies and care programs specifically for mobile populations may be crucial for achieving the ambitious goal of UNAIDS to end the epidemic by 2030. Finally, considerable debate exists as to the frequency of HIV testing needed for a UTT scenario to dramatically reduce the magnitude of the epidemic. This debate is centered primarily around the contribution of early and acute HIV (EHI) infection to onward transmission [23,24]. Although some argue that EHI threatens the population-level effectiveness of UTT [10,25], others assert that, despite elevated infectiousness of EHI [26], yearly UTT can theoretically lead to elimination [23,27]. Mathematical models of UTT on HIV transmission dynamics, however, have often relied on simplifying assumptions about sexual risk behavior in the period immediately following HIV infection; assuming, for example, that sexual contact rates remain constant from initial infection through the early infectious period [10]. In fact, the risk profile of newly infected individuals – most of whom are unaware of their HIV status – differs substantially from those who have been infected for longer periods of time [28], and theoretical simulation studies demonstrate that heterogeneity in sexual contact rates over time can dramatically increase the fraction of secondary infections that occur during EHI [29,30]. In this way, epidemics with similar basic reproductive numbers (R0) can theoretically exhibit considerable variability in the proportion of secondary transmissions that occur during EHI. Settings where EHIs account for a large fraction of secondary infections may present a serious challenge to the promise of UTT [31]. Efforts are currently underway to better characterize the epidemiologic profile of populations that contribute the most to secondary infections in high-burden settings of SSA [32]. More studies from SSA, however, are needed to fill empirical gaps in our understanding of the heterogeneity in sexual risk behaviors and the propensity of HIV transmission across the HIV care cascade. Further modeling studies are also needed to assess whether projected long-term incidence reductions from UTT are sensitive to parametric uncertainties around both transmission heterogeneity across the cascade of care and the proportion of secondary cases linked to EHI. Until these efforts are undertaken, our ability to evaluate and learn from early failures of UTT – as well as the reasons for potential successes – will be limited.

Acknowledgements

Conflicts of interest

There are no conflicts of interest.
  31 in total

1.  Episodic HIV Risk Behavior Can Greatly Amplify HIV Prevalence and the Fraction of Transmissions from Acute HIV Infection.

Authors:  Xinyu Zhang; Lin Zhong; Ethan Romero-Severson; Shah Jamal Alam; Christopher J Henry; Erik M Volz; James S Koopman
Journal:  Stat Commun Infect Dis       Date:  2012-11-01

2.  Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study.

Authors:  Tulio de Oliveira; Ayesha B M Kharsany; Tiago Gräf; Cherie Cawood; David Khanyile; Anneke Grobler; Adrian Puren; Savathree Madurai; Cheryl Baxter; Quarraisha Abdool Karim; Salim S Abdool Karim
Journal:  Lancet HIV       Date:  2016-12-01       Impact factor: 12.767

3.  Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidence.

Authors:  Jeffrey W Eaton; Timothy B Hallett
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

4.  HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies?

Authors:  Myron S Cohen; Christopher Dye; Christophe Fraser; William C Miller; Kimberly A Powers; Brian G Williams
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

5.  Gender, migration and HIV in rural KwaZulu-Natal, South Africa.

Authors:  Carol S Camlin; Victoria Hosegood; Marie-Louise Newell; Nuala McGrath; Till Bärnighausen; Rachel C Snow
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

6.  HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model.

Authors:  Anne Cori; Helen Ayles; Nulda Beyers; Ab Schaap; Sian Floyd; Kalpana Sabapathy; Jeffrey W Eaton; Katharina Hauck; Peter Smith; Sam Griffith; Ayana Moore; Deborah Donnell; Sten H Vermund; Sarah Fidler; Richard Hayes; Christophe Fraser
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

7.  Impact of Heterogeneity in Sexual Behavior on Effectiveness in Reducing HIV Transmission with Test-and-Treat Strategy.

Authors:  Ganna Rozhnova; Maarten F Schim van der Loeff; Janneke C M Heijne; Mirjam E Kretzschmar
Journal:  PLoS Comput Biol       Date:  2016-08-01       Impact factor: 4.475

8.  Sexual partnership age pairings and risk of HIV acquisition in rural South Africa.

Authors:  Adam Akullian; Anna Bershteyn; Daniel Klein; Alain Vandormael; Till Bärnighausen; Frank Tanser
Journal:  AIDS       Date:  2017-07-31       Impact factor: 4.177

9.  A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial.

Authors:  Richard Hayes; Sian Floyd; Ab Schaap; Kwame Shanaube; Peter Bock; Kalpana Sabapathy; Sam Griffith; Deborah Donnell; Estelle Piwowar-Manning; Wafaa El-Sadr; Nulda Beyers; Helen Ayles; Sarah Fidler
Journal:  PLoS Med       Date:  2017-05-02       Impact factor: 11.069

10.  Access to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP cluster-randomized trial in rural South Africa.

Authors:  Mélanie Plazy; Kamal El Farouki; Collins Iwuji; Nonhlanhla Okesola; Joanna Orne-Gliemann; Joseph Larmarange; France Lert; Marie-Louise Newell; François Dabis; Rosemary Dray-Spira
Journal:  J Int AIDS Soc       Date:  2016-06-01       Impact factor: 5.396

View more
  11 in total

1.  Gendered dimensions of population mobility associated with HIV across three epidemics in rural Eastern Africa.

Authors:  Carol S Camlin; Adam Akullian; Torsten B Neilands; Monica Getahun; Anna Bershteyn; Sarah Ssali; Elvin Geng; Monica Gandhi; Craig R Cohen; Irene Maeri; Patrick Eyul; Maya L Petersen; Diane V Havlir; Moses R Kamya; Elizabeth A Bukusi; Edwin D Charlebois
Journal:  Health Place       Date:  2019-05-29       Impact factor: 4.078

Review 2.  Mobility and its Effects on HIV Acquisition and Treatment Engagement: Recent Theoretical and Empirical Advances.

Authors:  Carol S Camlin; Edwin D Charlebois
Journal:  Curr HIV/AIDS Rep       Date:  2019-08       Impact factor: 5.071

3.  Predicting HIV Incidence in the SEARCH Trial: A Mathematical Modeling Study.

Authors:  Britta L Jewell; Laura B Balzer; Tamara D Clark; Edwin D Charlebois; Dalsone Kwarisiima; Moses R Kamya; Diane V Havlir; Maya L Petersen; Anna Bershteyn
Journal:  J Acquir Immune Defic Syndr       Date:  2021-08-01       Impact factor: 3.771

4.  Population mobility associated with higher risk sexual behaviour in eastern African communities participating in a Universal Testing and Treatment trial.

Authors:  Carol S Camlin; Adam Akullian; Torsten B Neilands; Monica Getahun; Patrick Eyul; Irene Maeri; Sarah Ssali; Elvin Geng; Monica Gandhi; Craig R Cohen; Moses R Kamya; Thomas Odeny; Elizabeth A Bukusi; Edwin D Charlebois
Journal:  J Int AIDS Soc       Date:  2018-07       Impact factor: 5.396

5.  Bringing population mobility into focus to achieve HIV prevention goals.

Authors:  Carol S Camlin; Susan Cassels; Janet Seeley
Journal:  J Int AIDS Soc       Date:  2018-07       Impact factor: 5.396

6.  Demographic and risk group heterogeneity across the UNAIDS 90-90-90 targets: a systematic review and meta-analysis protocol.

Authors:  Dylan Green; Brenda Kharono; Diana M Tordoff; Adam Akullian; Anna Bershteyn; Michelle Morrison; Geoff Garnett; Ann Duerr; Paul Drain
Journal:  Syst Rev       Date:  2019-05-06

Review 7.  Opportunities and Challenges in HIV Treatment as Prevention Research: Results from the ANRS 12249 Cluster-Randomized Trial and Associated Population Cohort.

Authors:  Frank Tanser; Hae-Young Kim; Alain Vandormael; Collins Iwuji; Till Bärnighausen
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

8.  A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings.

Authors:  David Bonsall; Tanya Golubchik; Mariateresa de Cesare; Mohammed Limbada; Barry Kosloff; George MacIntyre-Cockett; Matthew Hall; Chris Wymant; M Azim Ansari; Lucie Abeler-Dörner; Ab Schaap; Anthony Brown; Eleanor Barnes; Estelle Piwowar-Manning; Susan Eshleman; Ethan Wilson; Lynda Emel; Richard Hayes; Sarah Fidler; Helen Ayles; Rory Bowden; Christophe Fraser
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

9.  Progress Toward the 90-90-90 HIV Targets in Zimbabwe and Identifying Those Left Behind.

Authors:  Avi J Hakim; Beth A Tippett Barr; Steven Kinchen; Godfrey Musuka; Julius Manjengwa; Shungu Munyati; Lovemore Gwanzura; Owen Mugurungi; Getrude Ncube; Suzue Saito; Bharat S Parekh; Hetal Patel; Yen T Duong; Elizabeth Gonese; Katrina Sleeman; Leala Ruangtragool; Jessica Justman; Amy Herman-Roloff; Elizabeth Radin
Journal:  J Acquir Immune Defic Syndr       Date:  2021-11-01       Impact factor: 3.771

10.  The effect of 90-90-90 on HIV-1 incidence and mortality in eSwatini: a mathematical modelling study.

Authors:  Adam Akullian; Michelle Morrison; Geoffrey P Garnett; Zandile Mnisi; Nomthandazo Lukhele; Daniel Bridenbecker; Anna Bershteyn
Journal:  Lancet HIV       Date:  2020-02-13       Impact factor: 12.767

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.